A Brennan

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

A. Brennan, N. Bansback, N J Bansback, 2004, Annals of the rheumatic diseases.

Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.

A. Brennan, N. Bansback, J. Madan, 2007, Rheumatology.

The role of modelling in prioritising and planning clinical trials.

J Chilcott, J Karnon, P Tappenden, 2003, Health technology assessment.

Modelling in health economic evaluation. What is its place? What is its value?

A. Brennan, R. Akehurst, A Brennan, 2000, PharmacoEconomics.

Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.

A. Brennan, N. Bansback, P. Conway, 2004, Rheumatology.

Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis

K Khunti, M Gillett, M J Davies, 2010, BMJ : British Medical Journal.

Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry

D. Symmons, A. Brennan, N. Bansback, 2008 .

PAR15 USING MIXED TREATMENT COMPARISONS AND METAREGRESSION TO PERFORM INDIRECT COMPARISONS TO ESTIMATE THE EFFICACY OF BIOLOGIC TREATMENTS IN RHEUMATOID ARTHRITIS

A. Brennan, N. Bansback, R. Nixon, 2007 .